183 related articles for article (PubMed ID: 35008557)
1. CLDN6 Suppresses c-MYC-Mediated Aerobic Glycolysis to Inhibit Proliferation by TAZ in Breast Cancer.
Qu H; Qi D; Wang X; Dong Y; Jin Q; Wei J; Quan C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008557
[TBL] [Abstract][Full Text] [Related]
2. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
3. Betulinic acid suppresses breast cancer aerobic glycolysis via caveolin-1/NF-κB/c-Myc pathway.
Jiao L; Wang S; Zheng Y; Wang N; Yang B; Wang D; Yang D; Mei W; Zhao Z; Wang Z
Biochem Pharmacol; 2019 Mar; 161():149-162. PubMed ID: 30684465
[TBL] [Abstract][Full Text] [Related]
4. CLDN6 inhibited cellular biological function of nonsmall cell lung cancer cells through suppressing aerobic glycolysis via the RIP1/ASK1/JNK axis.
Guo H; Li J; Dong Y; Gao H; Wang P
J Biochem Mol Toxicol; 2024 Mar; 38(3):e23682. PubMed ID: 38462752
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy.
Song P; Li Y; Dong Y; Liang Y; Qu H; Qi D; Lu Y; Jin X; Guo Y; Jia Y; Wang X; Xu W; Quan C
J Exp Clin Cancer Res; 2019 Aug; 38(1):354. PubMed ID: 31412908
[TBL] [Abstract][Full Text] [Related]
6. CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling.
Lu Y; Shao Y; Xie Y; Qu H; Qi D; Dong Y; Jin Q; Wang L; Wei J; Quan C
Cell Signal; 2022 Sep; 97():110393. PubMed ID: 35752352
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
8. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.
Yang M; Li Y; Shen X; Ruan Y; Lu Y; Jin X; Song P; Guo Y; Zhang X; Qu H; Shao Y; Quan C
J Exp Clin Cancer Res; 2017 Nov; 36(1):157. PubMed ID: 29116019
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac.
Liu Y; Jin X; Li Y; Ruan Y; Lu Y; Yang M; Lin D; Song P; Guo Y; Zhao S; Dong B; Xie Y; Dang Q; Quan C
J Exp Clin Cancer Res; 2016 Jul; 35(1):120. PubMed ID: 27461117
[TBL] [Abstract][Full Text] [Related]
10. CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy.
Dong Y; Jin Q; Sun M; Qi D; Qu H; Wang X; Quan C
J Exp Clin Cancer Res; 2023 Mar; 42(1):68. PubMed ID: 36935496
[TBL] [Abstract][Full Text] [Related]
11. The expression and the tumor suppressor role of CLDN6 in colon cancer.
Qu H; Wang M; Wang M; Liu Y; Quan C
Mol Cell Biochem; 2022 Dec; 477(12):2883-2893. PubMed ID: 35701678
[TBL] [Abstract][Full Text] [Related]
12. EBP50 suppresses the proliferation of MCF-7 human breast cancer cells via promoting Beclin-1/p62-mediated lysosomal degradation of c-Myc.
Liu H; Zhao WL; Wang JP; Xin BM; Shao RG
Acta Pharmacol Sin; 2018 Aug; 39(8):1347-1358. PubMed ID: 29283175
[TBL] [Abstract][Full Text] [Related]
13. CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells.
Guo Y; Lin D; Zhang M; Zhang X; Li Y; Yang R; Lu Y; Jin X; Yang M; Wang M; Zhao S; Quan C
Int J Oncol; 2016 Jun; 48(6):2435-44. PubMed ID: 27035750
[TBL] [Abstract][Full Text] [Related]
14. Aberrant Claudin-6-Adhesion Signaling Promotes Endometrial Cancer Progression via Estrogen Receptor α.
Kojima M; Sugimoto K; Kobayashi M; Ichikawa-Tomikawa N; Kashiwagi K; Watanabe T; Soeda S; Fujimori K; Chiba H
Mol Cancer Res; 2021 Jul; 19(7):1208-1220. PubMed ID: 33727343
[TBL] [Abstract][Full Text] [Related]
15. A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis.
Jia Y; Guo Y; Jin Q; Qu H; Qi D; Song P; Zhang X; Wang X; Xu W; Dong Y; Liang Y; Quan C
J Exp Clin Cancer Res; 2020 Feb; 39(1):42. PubMed ID: 32093760
[TBL] [Abstract][Full Text] [Related]
16. SMAD2 Inactivation Inhibits CLDN6 Methylation to Suppress Migration and Invasion of Breast Cancer Cells.
Lu Y; Wang L; Li H; Li Y; Ruan Y; Lin D; Yang M; Jin X; Guo Y; Zhang X; Quan C
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28867761
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
[TBL] [Abstract][Full Text] [Related]
18. CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1/PTEN axis.
Dong Y; Xu W; Qi D; Qu H; Jin Q; Sun M; Wang X; Quan C
Cell Signal; 2023 Dec; 112():110930. PubMed ID: 37852424
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis.
Qin Y; Hu Q; Xu J; Ji S; Dai W; Liu W; Xu W; Sun Q; Zhang Z; Ni Q; Zhang B; Yu X; Xu X
Cell Commun Signal; 2019 Mar; 17(1):30. PubMed ID: 30922330
[TBL] [Abstract][Full Text] [Related]
20. Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer.
Zhang Y; Wang Y; Li Y; Huang C; Xiao X; Zhong Z; Tang J; Lu H; Tang Y; Yang J
Biochem Pharmacol; 2022 Apr; 198():114941. PubMed ID: 35149053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
